Krystal Biotech Inc. (KRYS)
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy.
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
